Metabolic Syndrome in Subjects with Type-2 Diabetes Mellitus
INTRODUCTION
The clustering of cardiovascular disease risk components found in persons with abnormal glucose tolerance (impaired glucose tolerance or diabetes mellitus) has been labeled variously as Syndrome X, the Insulin Resistance Syndrome, the Deadly Quartet, or metabolic syndrome (MS). The World Health Organization (WHO), has defined the syndrome to include a combination of impaired glucose regulation or diabetes, generic insulin resistance, raised arterial blood pressure, raised plasma triglycerides and/or low HDL-cholesterol, central obesity and/or BMI >30 kg nr2 and microalbuminuria. Each component of the cluster conveys increased cardiovascular disease risk, but as a combination they become much more powerful. This means that the management of persons with MS should focus not only on blood glucose control but also include strategies for reduction of the other cardiovascular disease risk factors. There is evidence that insulin drug resistance may be the common etiological factor for the individual components of the syndrome. Vigorous early management of the syndrome may have a significant impact on the prevention of both diabetes and cardiovascular disease.
Early detection of microalbuminuria requires the use of radioimmunoassay and dipsticks, such as Micral 1-Test immunoassay (Boehringer Mannheim, Mannheim, Germany), that are expensive and not always readily available in developing countries, such as Nigeria. Recently, some workers have shown that a combined negative sulfosalicylic acid test (SAT) result and a negative result on chemstrips, such as Albustic test (AT), virtually exclude microalbuminuria. canadian discount drugs
The aim of this study is to determine the frequency of MS at the Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria and its relation to cardiovascular morbidity and mortality.
